Insider Selling: Enfusion, Inc. (NYSE:ENFN) CEO Sells $32,029.20 in Stock

Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan sold 2,790 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total transaction of $32,029.20. Following the sale, the chief executive officer now directly owns 643,299 shares in the company, valued at $7,385,072.52. This trade represents a 0.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Oleg Movchan also recently made the following trade(s):

• On Thursday, March 6th, Oleg Movchan sold 11,452 shares of Enfusion stock. The shares were sold at an average price of $11.39, for a total transaction of $130,438.28.
• On Tuesday, January 7th, Oleg Movchan sold 2,771 shares of Enfusion stock. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23.

Enfusion Price Performance

Enfusion stock opened at $11.24 on Friday. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of 280.95, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95. The firm has a 50 day simple moving average of $10.98 and a 200-day simple moving average of $9.88. Enfusion, Inc. has a 1-year low of $7.83 and a 1-year high of $11.80.

Enfusion (NYSE:ENFN) last posted its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The company had revenue of $52.94 million for the quarter, compared to analysts’ expectations of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. Equities analysts expect that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enfusion

A number of hedge funds and other institutional investors have recently modified their holdings of the company. New York State Common Retirement Fund raised its holdings in shares of Enfusion by 23.8% in the 4th quarter. New York State Common Retirement Fund now owns 1,926,968 shares of the company’s stock valued at $19,848,000 after purchasing an additional 370,498 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Enfusion by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 1,050,549 shares of the company’s stock valued at $10,823,000 after purchasing an additional 21,183 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Enfusion by 6.1% in the 4th quarter. Wellington Management Group LLP now owns 1,035,996 shares of the company’s stock valued at $10,671,000 after purchasing an additional 59,700 shares in the last quarter. Azora Capital LP raised its holdings in shares of Enfusion by 3,255.9% in the 4th quarter. Azora Capital LP now owns 1,000,967 shares of the company’s stock valued at $10,310,000 after purchasing an additional 971,140 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Enfusion by 2.3% in the 3rd quarter. State Street Corp now owns 952,895 shares of the company’s stock valued at $9,043,000 after purchasing an additional 21,729 shares in the last quarter. 81.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ENFN. William Blair restated a “market perform” rating on shares of Enfusion in a research report on Monday, January 13th. Stifel Nicolaus upped their price target on shares of Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Finally, Piper Sandler upped their price target on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, December 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Enfusion presently has an average rating of “Hold” and a consensus target price of $11.13.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.